Welcome to our dedicated page for Zimmer Biomet Holdings news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet Holdings stock.
Zimmer Biomet Holdings, Inc. reports developments across its global medical technology business, including orthopedic reconstructive implants, surgical products, and integrated digital and robotic technologies that use data, analytics and artificial intelligence. Company updates commonly cover quarterly results and guidance, dividend actions, health care conference appearances, executive leadership changes, and clinical or operational data presented at orthopedic meetings.
Product-focused announcements describe musculoskeletal care technologies such as Oxford Cementless Partial Knee, Persona OsseoTi Keel Tibia, and HAMMR Automated Hip Impaction System, alongside broader portfolio themes in knees, hips, smart implants, robotics, AI and medical education.
Zimmer Biomet Holdings, Inc. (ZBH) announced important changes in its Executive Leadership Team on March 31, 2021. Lori Winkler has been appointed as the Chief Human Resources Officer (CHRO), having previously served as Group Vice President of Human Resources. Sang Yi has been promoted to Group President for Asia Pacific, a role he has held since June 2015. Both appointments are aimed at strengthening the company's human resources and regional operations as part of its mission to improve patient care globally.
Zimmer Biomet Holdings has appointed Ivan Tornos as Chief Operating Officer, effective March 19, 2021. Tornos, who joined the company in November 2018, will oversee all global businesses and lead operations, clinical education, and R&D. He continues to lead the Americas and now adds the EMEA region to his responsibilities. The company also announced Didier Deltort's departure as President of EMEA, effective immediately, with a search underway for his replacement. Tornos brings extensive experience from Becton, Dickinson, and C.R. Bard.
Zimmer Biomet Holdings has announced a quarterly cash dividend of $0.24 per share for the first quarter of 2021. The dividend is payable on April 30, 2021, to stockholders of record by March 29, 2021. The company continues to lead in musculoskeletal healthcare, providing a range of products for orthopedic reconstruction, sports medicine, and more. With operations in over 25 countries, Zimmer Biomet aims to enhance patient care through innovative solutions.
Zimmer Biomet Holdings announced significant changes to its Board of Directors. Sreelakshmi Kolli, Chief Digital Officer at Align Technology, joins the board immediately. Larry C. Glasscock, the Non-Executive Chairman, will retire in May 2021 as per governance guidelines. Following his retirement, Bryan C. Hanson, the current President and CEO, will assume the role of Chairman. Christopher B. Begley will become the Lead Independent Director. Additionally, Gail K. Boudreaux has opted not to seek reelection at the upcoming annual meeting. These changes reflect Zimmer Biomet's ongoing strategic initiatives.
Zimmer Biomet Holdings (NYSE: ZBH) announced that President and CEO Bryan Hanson and CFO Suky Upadhyay will present at the Cowen 41st Annual Health Care Conference on March 4, 2021, at 11:10 a.m. ET. The presentation will be accessible via a live webcast on Zimmer Biomet's Investor Relations website and will be archived for replay.
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a leader in musculoskeletal healthcare, providing innovative orthopedic and surgical products worldwide.
Zimmer Biomet Holdings, Inc. has appointed Vafa Jamali as the CEO of NewCo, a spin-off company which will focus on the Spine and Dental sectors, expected to launch in mid-2022. Jamali brings over 25 years of medical device experience, previously holding leadership roles at Rockley Photonics and Medtronic, where he led a $3 billion revenue division. His expertise is anticipated to drive growth and investment strategies for NewCo. Bryan Hanson, the current CEO of Zimmer Biomet, expressed confidence in Jamali’s ability to lead the new venture successfully.
Zimmer Biomet (ZBH) announced that President and CEO Bryan Hanson, along with Executive Vice President and CFO Suky Upadhyay, will present at Citi's 2021 Healthcare Services Conference on February 24, 2021, at 10:45 a.m. ET. A live webcast can be accessed via their Investor Relations website, which will also archive the presentation for later viewing. Zimmer Biomet, headquartered in Warsaw, Indiana, is a key player in musculoskeletal healthcare, offering a wide range of medical products and solutions.
Zimmer Biomet (NYSE: ZBH) plans to spin off its Spine and Dental businesses into a new independent company, NewCo, aiming to optimize growth and stakeholder value. This strategic move, part of Zimmer Biomet's transformation, focuses resources on higher-growth markets, including orthopedics and dental sectors. The spin-off, expected mid-2022, is designed to create stronger growth profiles for both companies while achieving a more targeted investment opportunity. The 2019 and 2020 pro forma revenue for Zimmer Biomet was $6.96 billion and $6.128 billion, respectively.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) reported its Q4 2020 results, revealing net sales of $2.085 billion, down 1.9%, with full-year sales at $7.025 billion, a 12% decrease. Q4 net earnings reached $333.7 million, equating to diluted EPS of $1.59, a 3.2% increase year-over-year. Adjusted diluted EPS fell 8.3% to $2.11. The company announced plans to spin off its Spine and Dental divisions to enhance focus and growth. Despite strong operational performance, the ongoing impact of COVID-19 on elective procedures continues to hinder recovery.
Zimmer Biomet Holdings has appointed Ellison M. Humphrey as the Chief Transformation Officer, reporting directly to Bryan C. Hanson, President and CEO. Humphrey joins from Medtronic, where she held leadership roles including Vice President of Enterprise Excellence. In her new role, she will connect key initiatives to drive an integrated transformation strategy across the organization. Her extensive experience, including a background at McKinsey & Company and degrees from Harvard and the University of Virginia, is expected to advance Zimmer Biomet’s goals within the evolving healthcare landscape.